Chloramphenicol eye drops are commonly prescribed in concentrations of 0.5-1% in the treatment of infectious conjunctivitis. In terms of ophthalmic solution preparation, the major disadvantage of chloramphenicol consists in its low solubility in water. The solubility is increased by substances that form chloramphenicol-complexes, for example: boric acid/borax or cyclodextrins. Objective: Experimental studies aimed to evaluate the potential advantages of enhancing the solubility and stability of chloramphenicol (API) by molecular encapsulation in b-cyclodextrin (CD), in formulation of ophthalmic solutions buffered with boric acid/borax system. Methods and Results: We prepared four APIb- CD complexes, using two methods (kneading and co-precipitation) and two molar ratio of API/b-cyclodextrin (1:1 and 1:2). The formation of complexes was proved by differential scanning calorimetry (DSC) and the in vitro dissolution tests. Using these compounds, we prepared eight ophthalmic solutions, formulated in two variants of chloramphenicol concentrations (0.4% and 0.5%). Each solution was analyzed, by the official methods, at preparation and periodically during three months of storing in different temperature conditions (4°C, 20°C and 30°C). Conclusions: Inclusion of chloramphenicol in b-cyclodextrin only partially solves the difficulties due to the low solubility of chloramphenicol. The protection of chloramphenicol molecules is not completely ensured when the ophthalmic solutions are buffered with the boric acid/borax system.
4. Vlaia L Lupuleasa D Coneac G et al- Prepararea medicamentelor- baze practice vol.I Ed. Mirton Timişoara 2009;331-340.
5. James KC Leach RH- A borax-chloramphenicol complex in aqueous solution Journal of Pharmacy and Pharmacology 1970; 22(8):612-614.
6. Boer Y Pijnenburg A- HPLC determination of chloramphenicol degradation in eye drops Pharmaceutisch Weekblad 1983;5(3):95-101.
7. Abdel Rahman AA Khidr SH Ahmed SM et al- Evaluation of chloramphenicol-b-cyclodextrin inclusion complex Eur. J. Pharm. Biopharm.1991;37(1):34-37.
8. Ramos AI Braga TM Silva P et al- Chloramphenicol-cyclodextrin inclusion compounds: co-dissolution and mechanochemical preparations and antibacterial action CrystEngComm 2013;15:2822-2834.
9. Zuorro A Fidaleo M Laveccia R- Solubility enhancement and antibacterial activity of chloramphenicol included in modified b-cyclodextrins Bull. Korean Chem. Soc. 2010;31(11):3460-3462.
10. Loftsson T Jarho P Másson M Järvinen T- Cyclodextrins in drug delivery: review Expert Opin. Frug Deliv. 2005;2:335-351.
11. Sipos E Kovács O Lörinczi L- Formulation and microbiology analysis of multidose eye drops obtained with inclusion complex of chloramphenicol Orvostudományi Értesitő 2009;82(4):287-288.
12. British Pharmacopoeia II-III University Press Cambridge London 2009;1239-418281-8282.
13. Menczel JD Prime RB et al- Differential Scanning Calorimetry (DSC) in “Thermal Analysis of Polymers: Fundamentals and Applications” Wiley Inc New Jersey USA 2009;7-240.
14. Young Z Meirong H Jianping Z et al.- DDSolver: An Add-In Program for Modeling and Comparision of Drug Dissolution Profiles The AAPS Journal 2010;12(3):263-271.
15. Motulsky HJ Christopoulos A- Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting GraphPad Software Inc Sandiego CA 2003 (www.graphpad.com);134-160.
16. Hibbert DB Gooding JJ- Data Analysis for Chemistry: An Introductory Guid For Students and Laboratory Scientist University Press Oxford 2006 (electronic edition);128-164.